Findings of Research Misconduct, 15256-15257 [2022-05659]
Download as PDF
<![CDATA[
15256
Federal Register / Vol. 87, No. 52 / Thursday, March 17, 2022 / Notices
ANNUALIZED BURDEN HOUR TABLE—Continued
Unit Activity Reporting ......................
MRC Unit Leader .............................
748
4
15/60
748
Total ...........................................
...........................................................
........................
10
........................
2,244
[FR Doc. 2022–05612 Filed 3–16–22; 8:45 am]
BILLING CODE 4150–47–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Findings of research
misconduct have been made against
Shuo Chen, Ph.D. (Respondent),
formerly a postdoctoral researcher,
Department of Physics, University of
California, Berkeley (UCB). Respondent
engaged in research misconduct in
research reported in a grant application
submitted for U.S. Public Health Service
(PHS) funds, specifically National
Institute of Neurological Disorders and
Stroke (NINDS), National Institutes of
Health (NIH), grant application K99
NS116562–01. The administrative
actions, including supervision for a
period of one (1) year, were
implemented beginning on February 28,
2022, and are detailed below.
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr.P.H., Acting
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 240,
Rockville, MD 20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Shuo Chen, Ph.D., University of
California, Berkeley: Based on the report
of an investigation conducted by UCB
and additional analysis conducted by
ORI in its oversight review, ORI found
that Dr. Shuo Chen, formerly a
postdoctoral researcher, Department of
Physics, UCB, engaged in research
misconduct in research reported in a
grant application submitted for PHS
funds, specifically NINDS, NIH, grant
application K99 NS116562–01.
ORI found that Respondent engaged
in research misconduct by intentionally,
knowingly, and/or recklessly falsifying
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Average
burden per
response
Respondents
(if necessary)
Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance
Officer, Office of the Secretary.
VerDate Sep<11>2014
17:38 Mar 16, 2022
Jkt 256001
Number of
respondents
Number of
responses per
respondents
Forms
(if necessary)
data and methods by altering, reusing,
and relabeling source two-photon
microscopy and electrophysiological
data to represent images of mouse
hippocampal neurons in the following
grant application:
• K99 NS116562–01, ‘‘Investigation
into network dynamics of hippocampal
replay sequences by ultrafast voltage
imaging,’’ submitted to NINDS, NIH, on
June 25, 2019.
ORI found that Respondent
intentionally, knowingly, and/or
recklessly falsified two-photon
microscopy and in vivo
electrophysiological activity images,
figure legends, and text descriptions of
hippocampal neurons from a mouse
running on a treadmill in a head-fixed
virtual reality (VR) set up. Specifically:
• Respondent reused an image of
visual cortex neurons to represent
fluorescence calcium imaging of
hippocampal neurons in Figure 6d and
its associated text and figure legend of
K99 NS116562–01.
• Respondent reused in vivo
electrophysiological data from control
mice of spatial receptive fields for all
recorded place cells during linear track
exploration sessions from Supplemental
Figure 1b from Nat Neurosci. 2018
Jul;21(7):996–1003 (doi: 10.1038/
s41593–018–0163–8) to represent
several sessions of two-photon
hippocampal calcium imaging of
progressive place fields, obtained from
multiple mice running on a treadmill in
a head-fixed VR set up, in Figure 6e and
its associated text and figure legend of
K99 NS116562–01.
Respondent neither admits nor denies
ORI’s findings of research misconduct.
The parties entered into a Voluntary
Settlement Agreement (Agreement) to
conclude this matter without further
expenditure of time, finances, or other
resources. The settlement is not an
admission of liability on the part of the
Respondent.
Respondent voluntarily agreed to the
following:
(1) Respondent will have his research
supervised for a period of one (1) year
beginning on February 28, 2022 (the
‘‘Supervision Period’’). Prior to the
submission of an application for PHS
support for a research project on which
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
Total
burden hours
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity in PHS-supported
research, Respondent will submit a plan
for supervision of Respondent’s duties
to ORI for approval. The supervision
plan must be designed to ensure the
integrity of Respondent’s research.
Respondent will not participate in any
PHS-supported research until such a
supervision plan is approved by ORI.
Respondent will comply with the
agreed-upon supervision plan.
(2) The requirements for Respondent’s
supervision plan are as follows:
i. A committee of 2–3 senior faculty
members at the institution who are
familiar with Respondent’s field of
research, but not including
Respondent’s supervisor or
collaborators, will provide oversight and
guidance during the Supervision Period.
The committee will review primary data
from Respondent’s laboratory on a
quarterly basis and submit a report to
ORI at six (6) month intervals setting
forth the committee meeting dates and
Respondent’s compliance with
appropriate research standards and
confirming the integrity of Respondent’s
research.
ii. The committee will conduct an
advance review of each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved. The review will include a
discussion with Respondent of the
primary data represented in those
documents and will include a
certification to ORI that the data
presented in the proposed application,
report, manuscript, or abstract is
supported by the research record.
(3) During the Supervision Period,
Respondent will ensure that any
institution employing him submits, in
conjunction with each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract.
E:\FR\FM\17MRN1.SGM
17MRN1
15257
Federal Register / Vol. 87, No. 52 / Thursday, March 17, 2022 / Notices
(4) If no supervision plan is provided
to ORI, Respondent will provide
certification to ORI at the conclusion of
the Supervision Period that his
participation was not proposed on a
research project for which an
application for PHS support was
submitted and that he has not
participated in any capacity in PHSsupported research.
(5) During the Supervision Period,
Respondent will exclude himself
voluntarily from serving in any advisory
or consultant capacity to PHS including,
but not limited to, service on any PHS
advisory committee, board, and/or peer
review committee.
Dated: March 14, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity,
Office of the Assistant Secretary for Health.
[FR Doc. 2022–05659 Filed 3–16–22; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Proposed Collection; 60-Day Comment
Request; National Cancer Institute
(NCI) Generic Clearance for
Application Information From Fellows,
Interns, and Trainees
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide
opportunity for public comment on
proposed data collection projects, the
National Cancer Institute (NCI) will
SUMMARY:
Comments regarding this
information collection are best assured
of having their full effect if received
within 60 days of the date of this
publication.
DATES:
To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Diane Kreinbrink, Program
Manager, Office of Management Policy
and Compliance, National Cancer
Institute, 9609 Medical Center Drive,
Room 1W706, Bethesda, Maryland,
20892 or call non-toll-free number (240)
276–7283 or email your request,
including your address to:
diane.kreinbrink@nih.gov. Formal
requests for additional plans and
instruments must be requested in
writing.
FOR FURTHER INFORMATION CONTACT:
Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: Written
comments and/or suggestions from the
public and affected agencies are invited
to address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
SUPPLEMENTARY INFORMATION:
National Institutes of Health
AGENCY:
collected; and (4) Ways to minimizes
the burden of the collection of
information on those who are to
respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Proposed Collection Title: Generic
Clearance for Application Information
from Fellows, Interns, and Trainees,
0925–0761, Expiration Date 07/31/2022,
EXTENSION, National Cancer Institute
(NCI), National Institutes of Health
(NIH).
Need and Use of Information
Collection: The ‘‘Generic Clearance for
Application Information from Fellows,
Interns, and Trainees’’ request supports
research experiences for high school,
post-baccalaureate (including post
masters) individuals, graduate students,
and postdoctoral fellows, interns, and
trainees in a multidisciplinary
environment at the NCI. This
information collection request is for
applications, reference letters, letters of
intent and interest, and other related
documentation necessary for various
Divisions, Offices, and Centers at NCI to
evaluate the eligibility, merits, and
quality of potential candidates. The
applications will also assist in matching
potential candidates to various training
and internship programs. The
information is for internal use to make
decisions about candidates invited to
visit and attend NCI fellowships,
internships, and other training
opportunities.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
7,500 hours.
publish periodic summaries of propose
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
khammond on DSKJM1Z7X2PROD with NOTICES
Category of respondent
Average
time per
response
(in hours)
Number of
responses per
respondent
Total annual
burden hours
Individuals (Applicants) ....................................................................................
Individuals (Reference Letters) ........................................................................
3,000
9,000
1
1
60/60
30/60
3,000
4,500
Totals ........................................................................................................
........................
12,000
........................
7,500
Dated: March 14, 2022.
Diane Kreinbrink,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
[FR Doc. 2022–05663 Filed 3–16–22; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:38 Mar 16, 2022
Jkt 256001
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
E:\FR\FM\17MRN1.SGM
17MRN1
]]>Agencies
[Federal Register Volume 87, Number 52 (Thursday, March 17, 2022)]
[Notices]
[Pages 15256-15257]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-05659]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made against Shuo
Chen, Ph.D. (Respondent), formerly a postdoctoral researcher,
Department of Physics, University of California, Berkeley (UCB).
Respondent engaged in research misconduct in research reported in a
grant application submitted for U.S. Public Health Service (PHS) funds,
specifically National Institute of Neurological Disorders and Stroke
(NINDS), National Institutes of Health (NIH), grant application K99
NS116562-01. The administrative actions, including supervision for a
period of one (1) year, were implemented beginning on February 28,
2022, and are detailed below.
FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Acting
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite
240, Rockville, MD 20852, (240) 453-8200.
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Shuo Chen, Ph.D., University of California, Berkeley: Based on the
report of an investigation conducted by UCB and additional analysis
conducted by ORI in its oversight review, ORI found that Dr. Shuo Chen,
formerly a postdoctoral researcher, Department of Physics, UCB, engaged
in research misconduct in research reported in a grant application
submitted for PHS funds, specifically NINDS, NIH, grant application K99
NS116562-01.
ORI found that Respondent engaged in research misconduct by
intentionally, knowingly, and/or recklessly falsifying data and methods
by altering, reusing, and relabeling source two-photon microscopy and
electrophysiological data to represent images of mouse hippocampal
neurons in the following grant application:
K99 NS116562-01, ``Investigation into network dynamics of
hippocampal replay sequences by ultrafast voltage imaging,'' submitted
to NINDS, NIH, on June 25, 2019.
ORI found that Respondent intentionally, knowingly, and/or
recklessly falsified two-photon microscopy and in vivo
electrophysiological activity images, figure legends, and text
descriptions of hippocampal neurons from a mouse running on a treadmill
in a head-fixed virtual reality (VR) set up. Specifically:
Respondent reused an image of visual cortex neurons to
represent fluorescence calcium imaging of hippocampal neurons in Figure
6d and its associated text and figure legend of K99 NS116562-01.
Respondent reused in vivo electrophysiological data from
control mice of spatial receptive fields for all recorded place cells
during linear track exploration sessions from Supplemental Figure 1b
from Nat Neurosci. 2018 Jul;21(7):996-1003 (doi: 10.1038/s41593-018-
0163-8) to represent several sessions of two-photon hippocampal calcium
imaging of progressive place fields, obtained from multiple mice
running on a treadmill in a head-fixed VR set up, in Figure 6e and its
associated text and figure legend of K99 NS116562-01.
Respondent neither admits nor denies ORI's findings of research
misconduct. The parties entered into a Voluntary Settlement Agreement
(Agreement) to conclude this matter without further expenditure of
time, finances, or other resources. The settlement is not an admission
of liability on the part of the Respondent.
Respondent voluntarily agreed to the following:
(1) Respondent will have his research supervised for a period of
one (1) year beginning on February 28, 2022 (the ``Supervision
Period''). Prior to the submission of an application for PHS support
for a research project on which Respondent's participation is proposed
and prior to Respondent's participation in any capacity in PHS-
supported research, Respondent will submit a plan for supervision of
Respondent's duties to ORI for approval. The supervision plan must be
designed to ensure the integrity of Respondent's research. Respondent
will not participate in any PHS-supported research until such a
supervision plan is approved by ORI. Respondent will comply with the
agreed-upon supervision plan.
(2) The requirements for Respondent's supervision plan are as
follows:
i. A committee of 2-3 senior faculty members at the institution who
are familiar with Respondent's field of research, but not including
Respondent's supervisor or collaborators, will provide oversight and
guidance during the Supervision Period. The committee will review
primary data from Respondent's laboratory on a quarterly basis and
submit a report to ORI at six (6) month intervals setting forth the
committee meeting dates and Respondent's compliance with appropriate
research standards and confirming the integrity of Respondent's
research.
ii. The committee will conduct an advance review of each
application for PHS funds, or report, manuscript, or abstract involving
PHS-supported research in which Respondent is involved. The review will
include a discussion with Respondent of the primary data represented in
those documents and will include a certification to ORI that the data
presented in the proposed application, report, manuscript, or abstract
is supported by the research record.
(3) During the Supervision Period, Respondent will ensure that any
institution employing him submits, in conjunction with each application
for PHS funds, or report, manuscript, or abstract involving PHS-
supported research in which Respondent is involved, a certification to
ORI that the data provided by Respondent are based on actual
experiments or are otherwise legitimately derived and that the data,
procedures, and methodology are accurately reported in the application,
report, manuscript, or abstract.
[[Page 15257]]
(4) If no supervision plan is provided to ORI, Respondent will
provide certification to ORI at the conclusion of the Supervision
Period that his participation was not proposed on a research project
for which an application for PHS support was submitted and that he has
not participated in any capacity in PHS-supported research.
(5) During the Supervision Period, Respondent will exclude himself
voluntarily from serving in any advisory or consultant capacity to PHS
including, but not limited to, service on any PHS advisory committee,
board, and/or peer review committee.
Dated: March 14, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity, Office of the Assistant
Secretary for Health.
[FR Doc. 2022-05659 Filed 3-16-22; 8:45 am]
BILLING CODE 4150-31-P
